에이프로젠

007460KOSPI의약품 제조업

58.5 / 100

Reference Date: 2026-06-10

Financial Score13.5 / 40

News Sentiment19.0 / 25

Momentum12.0 / 20

Disclosure14.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Surged 987.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Aprogen operates major businesses in hardfacing, steel sales, nuclear insulation, pharmaceuticals, and biopharmaceuticals, maintaining a leading position in the domestic hardfacing market. The biopharmaceutical division focuses on developing biosimilars and new drugs, successfully selling Remicade biosimilars in the Japanese market.

Number of Employees

311people

Average Salary

52.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

0.16Industry Average 0.897.0Point

Half of industry avg (excellent)

ROE

-31.28Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

16.33Industry Average 12.432.0Point

Higher than industry avg (caution)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼10.9% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼3.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -25.6% (declining, 3yr)

Detailed News Sentiment

5 totalPositive 4Neutral 1Negative 0Average Sentiment Score 76

Neutral
[바이오스냅] 온코닉, 신약 '자큐보' 멕시코서 허가 신청
온코닉테라퓨틱스의 멕시코 시장 진출 계획 발표로 에이프로젠과 직접적인 연관성이 확인되지 않음.
Positive
에이프로젠, 퇴행성 관절염 신약 임상시험 식약처 승인
에이프로젠의 퇴행성 관절염 신약 AP209가 임상시험 승인을 받아 임상 진입 기대감이 높아졌다.
Positive
美 FDA ‘임상 간소화’에…바이오시밀러 개발 전략 바뀔까
FDA의 바이오시밀러 임상 간소화 정책으로 에이프로젠의 개발 효율성이 향상될 가능성이 높아져 긍정적 영향 예상.

Detailed Momentum

52-week position5.0Point

52w mid range (44%)

Current 3,185Won52-week high 6,76052-week low 280

1-month return6.0Point

1m +987.03% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

12 totalPositive 2Neutral 10Negative 0

Neutral[기재정정]주요사항보고서(전환사채권발행결정)(자회사의 주요경영사항)2026-06-02
Neutral기업지배구조보고서공시2026-06-01
Neutral주식등의대량보유상황보고서(일반)2026-05-29
Positive유상증자또는주식관련사채등의발행결과(자율공시)2026-05-29
Neutral주요사항보고서(전환사채권발행결정)(자회사의 주요경영사항)2026-05-26